Additional Information

Overview
This CME monograph, authored by 12 expert faculty, provides an overview of recent studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care that are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients.

Learning Objectives

• Discuss considerations in assessing patients presenting with advanced NSCLC.
• Discuss considerations in determining first-line treatment options for patients presenting with advanced NSCLC.
• Discuss considerations in integrating supportive care and managing brain metastasis in treatment strategies for patients with advanced NSCLC.
• Implement appropriate treatment and supportive care strategies into practice in assessing, counseling and treating patients with advanced NSCLC.

See links below to access the online activity and a PDF of the monograph.

Program Director
Thomas J. Lynch, Jr, MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer Center at Yale – New Haven
New Haven, Connecticut

Program Faculty
Tracy T. Batchelor, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Tracey Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Panos Fidias, MD
Massachusetts General Hospital
Center for Thoracic Cancers
Boston, Massachusetts

Glenwood D. Goss, MD, FCPSA, FRCPC
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada

Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana

Daniel D. Karp, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Natasha Leighl, MD, MMSc, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Jennifer Temel, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Target Audience
Oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Companion CME Activity
A companion CME activity, Lung Cancer: Case Studies Assessing Novel Agents in First-Line Therapy, based on videotaped discussion of 4 cases by the same program faculty.

Educational Grant Support
Supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.

Sponsorship
CME sponsorship provided by InforMEDical Communications, Inc.

The online CME activity has expired.